IGM Biosciences, Inc. (IGMS)
| Market Cap | 517.06M |
| Revenue (ttm) | 1.59M |
| Net Income (ttm) | -228.52M |
| Shares Out | 43.20M |
| EPS (ttm) | -5.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 97,458 |
| Open | 13.36 |
| Previous Close | 13.60 |
| Day's Range | 11.94 - 13.56 |
| 52-Week Range | 9.74 - 28.20 |
| Beta | -0.24 |
| Analysts | Buy |
| Price Target | 28.63 (+139.28%) |
| Earnings Date | May 12, 2023 |
About IGMS
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for IGMS stock is "Buy." The 12-month stock price forecast is $28.63, which is an increase of 139.28% from the latest price.
News
IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development
– Additional data from Phase 1 combination with FOLFIRI continues to show encouraging activity in median third-line metastatic colorectal cancer patients –
Medivir has completed the dose escalation part (phase 1b) of the 1b/2a study in HCC and focuses on the combination of fostrox and Lenvima
STOCKHOLM , June 2, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, anno...
IGM Biosciences to Present at the Jefferies Healthcare Conference
MOUNTAIN VIEW, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, toda...
Medivir to present at the Redeye Growth Day
STOCKHOLM , June 1, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, annou...
IGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis
Imvotamab, a CD20 x CD3 bispecific monoclonal antibody, offers potential for deeper B cell depletion than currently approved therapies Imvotamab, a CD20 x CD3 bispecific monoclonal antibody, offers po...
Change in the number of shares and votes in Medivir AB (publ)
STOCKHOLM , May 31, 2023 /PRNewswire/ -- Medivir AB (publ) ("Medivir") (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during May 2023 as a result o...
IGM Biosciences to Host Conference Call and Webcast to Provide IGM-8444 Clinical Update
– Event to be webcast live on Friday, June 2, 2023 at 7:00 p.m. ET – MOUNTAIN VIEW, Calif.
Medivir to present at the ABGSC Life Science Summit
STOCKHOLM , May 30, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, annou...
Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2023
HUDDINGE, Sweden , May 16, 2023 /PRNewswire/ -- In light of the incentive program adopted by the annual general meeting of Medivir AB (publ) ("Medivir") on 4 May 2023 ("LTIP 2023"), it is today announ...
IGM Biosciences Announces First Quarter 2023 Financial Results and Provides Corporate Update
– Randomized clinical trial of IGM-8444 plus FOLFIRI and bevacizumab in second line metastatic colorectal cancer underway –
Execution of the annual general meeting's resolution on the removal of share class in Medivir AB (publ)
STOCKHOLM , May 4, 2023 /PRNewswire/ -- The annual general meeting in Medivir AB (publ), held earlier today on 4 May 2023, resolved to adopt new articles of association, whereby the share class A is r...
Resolutions at the Annual General Meeting in Medivir on 4 May 2023
STOCKHOLM , May 4, 2023 /PRNewswire/ -- Medivir Aktiebolag (publ) held its annual general meeting today on 4 May 2023. The annual general meeting was held by physical presence of shareholders and with...
IGM Biosciences to Present at Two Upcoming Investor Conferences
MOUNTAIN VIEW, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today...
IGM Biosciences to Present at the Stifel 2023 Targeted Oncology Days
MOUNTAIN VIEW, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, tod...
IGM Biosciences Announces Six Presentations at the American Society for Cancer Research Annual Meeting 2023
Presentations highlight data from across all oncology pipeline programs Presentations highlight data from across all oncology pipeline programs
Notice of Annual General Meeting of Medivir AB (publ)
STOCKHOLM , March 31, 2023 /PRNewswire/ -- The shareholders of Medivir AB (publ), reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to the annual general mee...
IGM Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
– Encouraging initial data from IGM-8444 combination with FOLFIRI; first patient dosed in randomized trial –
IGM Biosciences to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on March 30, 2023
MOUNTAIN VIEW, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, tod...
First patient dosed in the phase 2a part of Medivir's study with fostrox in combination with Lenvima®
STOCKHOLM , March 14, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, ann...
Medivir to present at the Erik Penser Bank Healthcare Day
STOCKHOLM , Feb. 23, 2023 /PRNewswire/ -- Medivir AB (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces t...
Pia Baumann takes up her position as Chief Medical Officer
STOCKHOLM , Feb. 21, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, anno...
IGM Biosciences to Present at the Guggenheim 2023 Oncology Conference
MOUNTAIN VIEW, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, toda...
IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-7354 in Solid Tumors
– Targeted IL-15/IL-15R IgM antibody to be evaluated for safety and pharmacodynamic effects – – Targeted IL-15/IL-15R IgM antibody to be evaluated for safety and pharmacodynamic effects –
IGM Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
MOUNTAIN VIEW, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced...
Medivir has completed a successful pre-IND meeting with the FDA
STOCKHOLM , Dec. 12, 2022 /PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical ne...